# Newsletter

## Meetings

**Tuesday 03/27/12  12:00 noon**  
**Grand Rounds**  
“Diagnosis and Medical Management of Tardive Dyskinesia”  
Theresa Zesiewicz, MD FAAN  
Professor of Neurology, University of South Florida  
Director, USF Ataxia Research Center  
Founder and Director, The Frances J. Zesiewicz Center and Foundation for Parkinson’s Disease at USF

**Thursday 03/29/12  8:00 a.m.**  
**Call Center Meeting**

**Resident Lectures:**  
8:00 a.m.  
PGY-3 – “Psychodynamic Theories – Drive and Ego”  
Dr. John Hartman  
CHILD – Child Clinical Practice Exercise  
9:00 a.m.  
PGY-3 – “Clinical Case Conference”  
Dr. Kailie Shaw and Beth Reese, LCSW  
PGY-4 – “Group Therapy” Dr. John Zak  
10:00 a.m.  
PGY-3 and PGY-4 – “Board Review Series – Schizophrenia” Dr. Sarah Reading  
11:00 a.m.  
Residents Meeting  
1:00 p.m.  
PGY-1 – “Basic Elements of Psychotherapy”  
Dr. Robert Fernandez  
2:00 p.m.  
PGY-2 – “Introduction to Child – Parenting”  
Dr. Saundra Stock

**Friday 03/30/12**  
**Third Year Medical Students**  
8:30 a.m.  
Psychiatry NBME  
1:00 p.m.  
Neurology Exam
Happy Birthday Wishes to Kristine McGill/March 28th.

Congratulations to Dr. Michelle Mattingly for being appointed by the Board of the National Academy of Neuropsychology as the incoming editor of the NAN Bulletin.

Congratulations to Dr. Demian Obregon whose following abstract was accepted for the poster session at the Florida Psychiatric Society meeting, April 13-15, 2012:

Autoactive-Aβ antibodies promote APP β-secretase processing


Several prior investigations of Alzheimer's disease (AD) patients have indicated autoantibodies against amyloid-β (Aβ) species are produced. Although many studies have focused on the relative concentrations or binding affinities of autoantibodies against Aβ-related proteins in AD and aging, data regarding their functional properties are limited. It is generally believed that these antibodies act to aid in clearance of Aβ. However, as antibodies which bind to Aβ also typically bind to the parent amyloid precursor protein (APP), we reasoned that certain Aβ-targeting autoantibodies may bind to APP thereby altering its conformation and processing. Here we show for the first time, that naturally occurring Aβ-reactive autoantibodies isolated from AD patients, but not from healthy controls, promote β-secretase activity in cultured cells. Furthermore, using monoclonal antibodies to various regions of Aβ, we found that antibodies generated against the N-terminal region, especially Aβ1-17, dose dependently promoted amyloidogenic processing of APP via β-secretase activation. Thus, this property of certain autoantibodies in driving Aβ generation could be of etiological importance in the development of sporadic forms of AD and may guide the development of safe immunotherapies for AD.

For information regarding the USF Memory Disorders Clinic, please click on the following link: http://health.usf.edu/medicine/psychiatry/p_memory_disorders_clinic.htm

Research Happenings!

For information regarding current clinical trials, please go to the following website: http://health.usf.edu/medicine/psychiatry/index.htm

Current Open Studies – Call 813-974-2832 or 813-974-1404 for more information on any study or to refer a patient.

Now Open and Enrolling – ADHD Aggression Study

Kids between ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial. They must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator – Mike Bengtson, MD.
**Bipolar I in Teens**
This study is a 3-week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder experiencing a manic or mixed episode. A 26-week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator – Mike Bengtson, MD.

**Now Enrolling - Major Depression - Mixed**
A 6-week double-blind study comparing lurasidone to placebo in patients with major depression who are also experiencing some hypomanic symptoms. A 12-week open-label extension study is available. This study is looking at patient who may meet proposed DSM-V criteria for Major Depression – Mixed. PI – Carlos Santana, MD

**Now Enrolling – Bipolar**
A 9-month outpatient study of Ramelteon sub-lingual as an adjunctive treatment to prevent relapse of manic/mixed/depressive symptoms in patients 18-75 years who have experienced a manic/mixed/depressed episode within the last 9 months. Patients will continue on current mood stabilizers, antidepressants, or antipsychotic medications throughout the trial. PI – Carlos Santana, MD

**Now Enrolling – Bipolar I Disorder with Depressive Symptoms**
An 8-week outpatient study assessing Ramelteon sub-lingual as an adjunctive treatment for patients 18-75 years who are currently experiencing depressive symptoms associated with Bipolar I Disorder. Patients must be on Lithium and/or Depakote. PI – Carlos Santana, MD

**Now Enrolling – Schizophrenia Long-Acting IM Depot Open-label Study**
An open-label naturalistic study of Aripiprazole IM (long-acting depot) in patients with schizophrenia 18-65 years. Patients must have been prescribed antipsychotic medication for at least 7 months prior to enrollment and have had at least 1 Inpatient Hospitalization in the past 24 months. PI – Carlos Santana, MD

**http://health.usf.edu/medicine/psychiatry/research/index.htm**

**Quality of Life in Youth with Tic Disorders**
A one-time study visit evaluating the quality of life in youth with tic disorders, specifically on various aspects of family functioning and the daily challenges faced by children and their families. Children ages 6-17 years old with a diagnosis of a tic disorder (i.e. Chronic tic disorder or Tourette Syndrome) and are experiencing current tics are eligible to participate. This study is a one-time visit that will include questionnaires and assessments. Participants will also have the opportunity to attend a focus group with youth of similar age assessing kinds of help they received and accessibility of services and the difficulties faced by having tics. Please call (727) 767-8230 for more information. Principal Investigator: Tanya Murphy, MD
Child and Adolescent Tourette's Disorder Guanfacine Clinical Trial
The purpose of this research study is to learn more about the new extended release formula of the drug, guanfacine. This new formula is called *Intuniv*. This study will help us understand how safe and how well this new extended release formula of guanfacine works for children with chronic tics. Your child is being asked to take part in this research study because he/she has been diagnosed with Chronic Motor or Vocal Tic Disorder or Tourette's Disorder. Main symptoms are motor tics such as uncontrolled movements and/or vocal tics such as repeated noises. These tics occur many times a day, nearly every day lasting for at least 1 year. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information.
Principal Investigator: Tanya Murphy, MD

Living with Tics:The Living with Tics research study hopes to show how well a type of psychotherapy helps children better cope with tics and become more resilient. Children who are interested to participate must attend an initial assessment to determine eligibility. Eligible participants must be between 8 and 18 years of age, have a diagnosis of Tourette Syndrome or Chronic Tic Disorder, experience tic-related impairment, and either be medication-free or on stable medication. If eligible, interested participants will be randomly assigned to receive immediate psychotherapy or a 10 week waitlist control condition followed by subsequent psychotherapy. As part of the study, there is no charge for the psychotherapy treatment. The immediate psychotherapy condition consists of weekly therapy sessions over a 10 week period. This multi-component treatment approach includes habit reversal training, anger management, problem solving skills and other related therapeutic components to help improve the quality of life for children with chronic tic disorders. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD.

Adult OCD Ondansetron Clinical Trial
The purpose of this research study is to investigate the effectiveness, safety, and tolerability of 2 dosages Ondansetron as compared to placebo (a substance which looks like an active drug but has no active ingredient) in adult who have OCD and who are currently taking a selective serotonin reuptake inhibitor (SRI) such as Anafranil® (clomipramine) Paxil® (paroxetine), Prozac® (fluoxetine), Luvox® (fluvoxamine, or Zoloft® (sertraline). Another purpose of this study is to find out how the study drug works in the body when taken along with an SSRI. Please call (727) 767-8230 for more information.
Principal Investigator: Tanya Murphy, MD

Pediatric OCD D-Cycloserine and Cognitive Behavioral Therapy (CBT) Research Study
The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate. Please call (727) 767-8230 for more information.
Principal Investigator: Eric Storch PhD
Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study
The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information. Principal Investigator: Eric Storch PhD